Eli Lilly joins frenzy with $175m in sales of its weight loss drug Zepbound in just weeks 

Demand for Zepbound, a powerful rival to Novo Nordisk's weight-loss therapy Wegovy, is expected to outpace supply in 2024 even as Lilly expands the drug's manufacturing.

Eli Lilly has reported market-beating sales for its obesity drug Zepbound, just a few weeks after the launch of the weight-loss treatment in early December.

The drug brought in sales of $175.8m (€164m) in the fourth quarter to the end of December compared with expectations of $129m.